Abstract: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR), which can specifically binds to the EGFR, and can inhibit tumor growth by blocking ligand binding. A great deal of preclinical and clinical trials have confirmed the anti-tumor effect of Cetuximab alone or combining with chemotherapy and/or radiotherapy. Furthermore, it also has very extensive applied perspective in aspects of nuclear medicine, imaging and vaccine researches et al.